FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by the FDA in its first filing.